TY - JOUR
T1 - Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
AU - Hideshima, Teru
AU - Catley, Laurence
AU - Raje, Noopur
AU - Chauhan, Dharminder
AU - Podar, Klaus
AU - Mitsiades, Constantine
AU - Tai, Yu Tzu
AU - Vallet, Sonia
AU - Kiziltepe, Tanyel
AU - Ocio, Enrique
AU - Ikeda, Hiroshi
AU - Okawa, Yutaka
AU - Hideshima, Hiromasa
AU - Munshi, Nikhil C.
AU - Yasui, Hiroshi
AU - Richardson, Paul G.
AU - Anderson, Kenneth C.
PY - 2007/9
Y1 - 2007/9
N2 - Akt mediates growth and drug resistance in multiple myeloma (MM) cells in the bone marrow (BM) microenvironment. We have shown that a novel Akt inhibitor Perifosine induces significant cytotoxicity in MM cells in the BM milieu. This study further delineated molecular mechanisms whereby Perifosine triggered cytotoxicity in MM cells. Neither the intensity of Jun NH2-terminal kinase phosphorylation nor caspase/poly (ADP-ribose) polymerase cleavage correlated with Perifosine-induced cytotoxicity in MM.1S, INA6, OPM1 and OPM2 MM cells. However, survivin, which regulates caspase-3 activity, was markedly downregulated by Perifosine treatment, without changes in other anti-apoptotic proteins. Downregulation of survivin by siRNA significantly inhibited OPM1 MM cell growth, confirming that survivin mediates MM cell survival. Perifosine significantly downregulated both function and protein expression of β-catenin. Co-culture with BM stromal cells (BMSCs) upregulated both β-catenin and survivin expression in MM cells, which was blocked by Perifosine. Importantly, Perifosine treatment also downregulated survivin expression in human MM cells grown in vivo in a severe combined immunodeficient mouse xenograft model. Finally, Perifosine inhibited bortezomib-induced upregulation of survivin, associated with enhanced cytotoxicity of combined bortezomib and Perifosine treatment. These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM.
AB - Akt mediates growth and drug resistance in multiple myeloma (MM) cells in the bone marrow (BM) microenvironment. We have shown that a novel Akt inhibitor Perifosine induces significant cytotoxicity in MM cells in the BM milieu. This study further delineated molecular mechanisms whereby Perifosine triggered cytotoxicity in MM cells. Neither the intensity of Jun NH2-terminal kinase phosphorylation nor caspase/poly (ADP-ribose) polymerase cleavage correlated with Perifosine-induced cytotoxicity in MM.1S, INA6, OPM1 and OPM2 MM cells. However, survivin, which regulates caspase-3 activity, was markedly downregulated by Perifosine treatment, without changes in other anti-apoptotic proteins. Downregulation of survivin by siRNA significantly inhibited OPM1 MM cell growth, confirming that survivin mediates MM cell survival. Perifosine significantly downregulated both function and protein expression of β-catenin. Co-culture with BM stromal cells (BMSCs) upregulated both β-catenin and survivin expression in MM cells, which was blocked by Perifosine. Importantly, Perifosine treatment also downregulated survivin expression in human MM cells grown in vivo in a severe combined immunodeficient mouse xenograft model. Finally, Perifosine inhibited bortezomib-induced upregulation of survivin, associated with enhanced cytotoxicity of combined bortezomib and Perifosine treatment. These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM.
KW - β-catenin
KW - Akt
KW - Multiple myeloma
KW - Perifosine
KW - Survivin
UR - http://www.scopus.com/inward/record.url?scp=34548181762&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2007.06714.x
DO - 10.1111/j.1365-2141.2007.06714.x
M3 - Journal article
C2 - 17760810
AN - SCOPUS:34548181762
SN - 0007-1048
VL - 138
SP - 783
EP - 791
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 6
ER -